Form 4: Kymera COO Executes Stock Option Exercises and Sales

Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick exercised stock options and sold shares under a Rule 10b5-1 trading plan.

Summary

• Jeremy G. Chadwick, Chief Operating Officer of Kymera Therapeutics, exercised options to acquire 6,551 shares of common stock.
• The exercises occurred on April 14 and April 15, 2026, at strike prices of $30.17 and $43.50.
• Following the exercises, the reporting person sold 6,551 shares at a weighted average price of $90.00 per share.
• All transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were executed under a pre-arranged 10b5-1 plan and represent standard portfolio management by an executive.

Positives

• The transactions were pre-planned under a Rule 10b5-1 trading plan, indicating a systematic approach to equity management rather than reactive selling.
• The executive maintains a significant remaining beneficial ownership of 61,202 shares of common stock.

Negatives

• The executive reduced their direct holdings through the sale of 6,551 shares.

Risks

• Future equity compensation and ownership levels are subject to the executive's continued employment with the company.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard practice for biotech executives to manage personal liquidity and tax obligations, and does not typically signal a lack of confidence in the company's clinical pipeline.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to avoid potential conflicts of interest or allegations of insider trading.
• The volume of shares sold represents a small fraction of the executive's total holdings, which is consistent with typical executive compensation liquidation patterns.

Stakeholder Impact

• Minimal impact on shareholders as the transactions were pre-planned and disclosed in accordance with SEC regulations.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Kymera Therapeutics, KYMR, Insider Trading, Form 4, Stock Options, Biotech